LipoCol Forte capsules reduce the risk of liver cancer: A propensity score-matched, nationwide, population-based cohort study

doi:10.4251/wjgo.v15.i5.828

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2719)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-5) series.

Item

Count

PDF

103

WORD

HTML

1600

Figures (1-2)

193

Tables (1-5)

226

Sum=2148

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

143

Download

428

Sum=571

May 15, 2023 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastrointest Oncol. May 15, 2023; 15(5): 828-842
Published online May 15, 2023. doi: 10.4251/wjgo.v15.i5.828

Table 5 The risk of liver cancer by stratified follow-up years

Follow-up time	Non-LFC users			LFC users			cHR	95%CI	aHR¹	95%CI
Follow-up time	n	PY	IR	n	PY	IR	cHR	95%CI	aHR¹	95%CI
2-3 yr	1367	93294	14.65	1332	92819	14.35	0.98	(0.91, 1.06)	1.01	(0.93, 1.09)
4-6 yr	1554	63868	24.33	1401	64063	21.87	0.9	(0.84, 0.97)^b	0.92	(0.86, 0.99)^a
> 6 yr	927	29442	31.49	967	35241	27.44	0.77	(0.7, 0.84)^c	0.75	(0.68, 0.82)^c

¹Adjusted in multivariate analysis by sex, age, comorbidities and medications.

^aP < 0.05.

^bP < 0.01.

^cP < 0.001.

LFC: LipoCol Forte capsules; PY: Person-years; IR: Incidence rate per 1000 person-years; cHR: Crude hazard ratio; aHR: Adjusted hazard ratio.

Citation: Lai HC, Lin HJ, Shih YH, Chou JW, Lin KW, Jeng LB, Huang ST. LipoCol Forte capsules reduce the risk of liver cancer: A propensity score-matched, nationwide, population-based cohort study. World J Gastrointest Oncol 2023; 15(5): 828-842
URL: https://www.wjgnet.com/1948-5204/full/v15/i5/828.htm
DOI: https://dx.doi.org/10.4251/wjgo.v15.i5.828